Live Updates: COVID-19 Cases
  • World 21,175,952
    Confirmed: 21,175,952
    Active: 6,428,673
    Recovered: 13,987,884
    Death: 759,395
  • USA 5,431,381
    Confirmed: 5,431,381
    Active: 2,415,103
    Recovered: 2,845,496
    Death: 170,782
  • Brazil 3,229,621
    Confirmed: 3,229,621
    Active: 767,417
    Recovered: 2,356,640
    Death: 105,564
  • India 2,506,247
    Confirmed: 2,506,247
    Active: 686,677
    Recovered: 1,770,682
    Death: 48,888
  • Russia 912,823
    Confirmed: 912,823
    Active: 174,361
    Recovered: 722,964
    Death: 15,498
  • South Africa 572,865
    South Africa
    Confirmed: 572,865
    Active: 123,978
    Recovered: 437,617
    Death: 11,270
  • Peru 507,996
    Confirmed: 507,996
    Active: 134,342
    Recovered: 348,006
    Death: 25,648
  • Mexico 505,751
    Confirmed: 505,751
    Active: 108,951
    Recovered: 341,507
    Death: 55,293
  • Chile 380,034
    Confirmed: 380,034
    Active: 16,604
    Recovered: 353,131
    Death: 10,299
  • Spain 358,843
    Confirmed: 358,843
    Active: 330,226
    Recovered: ?
    Death: 28,617
  • Iran 338,825
    Confirmed: 338,825
    Active: 25,683
    Recovered: 293,811
    Death: 19,331
  • UK 313,798
    Confirmed: 313,798
    Active: 272,440
    Recovered: ?
    Death: 41,358
  • Saudi Arabia 295,902
    Saudi Arabia
    Confirmed: 295,902
    Active: 29,605
    Recovered: 262,959
    Death: 3,338
  • Pakistan 287,300
    Confirmed: 287,300
    Active: 15,932
    Recovered: 265,215
    Death: 6,153
  • Bangladesh 271,881
    Confirmed: 271,881
    Active: 111,667
    Recovered: 156,623
    Death: 3,591
  • Italy 252,809
    Confirmed: 252,809
    Active: 14,249
    Recovered: 203,326
    Death: 35,234
  • Turkey 245,635
    Confirmed: 245,635
    Active: 11,666
    Recovered: 228,057
    Death: 5,912
  • Germany 222,487
    Confirmed: 222,487
    Active: 12,404
    Recovered: 200,800
    Death: 9,283
  • France 209,365
    Confirmed: 209,365
    Active: 95,505
    Recovered: 83,472
    Death: 30,388
  • Canada 121,414
    Confirmed: 121,414
    Active: 4,602
    Recovered: 107,793
    Death: 9,019
  • China 84,786
    Confirmed: 84,786
    Active: 690
    Recovered: 79,462
    Death: 4,634
  • Netherlands 61,840
    Confirmed: 61,840
    Active: 55,673
    Recovered: ?
    Death: 6,167
  • Australia 22,743
    Confirmed: 22,743
    Active: 9,018
    Recovered: 13,350
    Death: 375
  • S. Korea 14,873
    S. Korea
    Confirmed: 14,873
    Active: 705
    Recovered: 13,863
    Death: 305
  • New Zealand 1,602
    New Zealand
    Confirmed: 1,602
    Active: 49
    Recovered: 1,531
    Death: 22

Pfizer, BioNTech experimental COVID-19 vaccine shows promising results: Study

Author at TechGenyz Health
Blue And Red Men With Syringe
Blue And Red Man With Syringe Represents Vaccination. Credit: @morningbrew/Unsplash

The American pharmaceutical giant Pfizer Inc. and the European biotechnology company BioNTech SE have conducted an experimental trial of a COVID-19 vaccine candidate and found it to be safe, well-tolerated, and capable of generating antibodies in the patients.

The study, which is yet to be peer-reviewed, describes the preliminary clinical data for the candidate vaccine — nucleoside-modified messenger RNA (modRNA), BNT162b1.

It said the amount of antibodies produced in participants after they received two shots of the vaccine candidate was greater than that reported in patients receiving convalescent plasma from recovered COVID-19 patients.

“I was glad to see Pfizer put up their phase 1 trial data today. Virus neutralizing antibody titers achieved after two doses are greater than convalescent antibody titers,” tweeted Peter Hotez, a vaccine scientist from Baylor College of Medicine in the US, who was unrelated to the study.

Researchers, including those from New York University in the US, who were involved in the study, said the candidate vaccine enables human cells to produce an optimized version of the receptor-binding domain (RBD) antigen — a part of the spike (S) protein of SARS-CoV-2 which it uses to gain entry into human cells.

“Robust immunogenicity was observed after vaccination with BNT162b1,” the scientists noted in the study.

They said the program is evaluating at least four experimental vaccines, each of which represents a unique combination of mRNA format and target component of the novel coronavirus, SARS-CoV-2.

Based on the study’s findings, they said BNT162b1 could be administered in a quantity that was well tolerated, potentially generating a dose dependent production of immune system molecules in the patients.

The research noted that patients treated with the vaccine candidate produced nearly 1.8 to 2.8 fold greater levels of RBD-binding antibodies that could neutralise SARS-CoV-2.

“We are encouraged by the clinical data of BNT162b1, one of four mRNA constructs we are evaluating clinically, and for which we have positive, preliminary, topline findings,” said Kathrin U. Jansen, study co-author and Senior Vice President and Head of Vaccine Research & Development, Pfizer.

“We look forward to publishing our clinical data in a peer-reviewed journal as quickly as possible,” Jansen said.

According to Ugur Sahin, CEO and Co-founder of BioNTech, and another co-author of the study, the preliminary data are encouraging as they provide an initial signal that BNT162b1 is able to produce neutralising antibody responses in humans.

He said the immune response observed in the patients treated with the experimental vaccine are at, or above, the levels observed from convalescent sera, adding that it does so at “relatively low dose levels.”

“We look forward to providing further data updates on BNT162b1,” Sahin said.

According to a statement from Pfizer, the initial part of the study included 45 healthy adults 18 to 55 years of age.

It said the priliminary data for BNT162b1 was evaluated in 24 subjects who received two injections of 10 microgrammes ( g) and 30 g — 12 subjects who received a single injection of 100 g, and 9 subjects who received two doses of a dummy vaccine.

The study noted that participants received two doses, 21 days apart, of placebo, 10 g or 30 g of BNT162b1, or received a single dose of 100 g of the vaccine candidate.

According to the scientists, the highest neutralising concentrations of antibodies were observed seven days after the second dose of 10 g, or 30 g on day 28 after vaccination.

They said the neutralising concentrations were 1.8- and 2.8-times that observed in a panel of 38 blood samples from people who had contracted the virus.

In all 24 subjects who received two vaccinations at 10 g and 30 g dose levels, elevation of RBD-binding antibody concentrations was observed after the second injection, the study noted.

It said these concentrations are 8- and 46.3-times the concentration seen in a panel of 38 blood samples from those infected with the novel coronavirus.

At the 10 g or 30 g dose levels, the scientists said adverse reactions, including low grade fever, were more common after the second dose than the first dose.

According to Pfizer, local reactions and systemic events after injection with 10 g and 30 g of BNT162b1 were “dose-dependent, generally mild to moderate, and transient.”

It said the most commonly reported local reaction was injection site pain, which was mild to moderate, except in one of 12 subjects who received a 100 g dose, which was severe.

The study noted that there was no serious adverse events reported by the patients.

Citing the limitations of the research, the scientists said the immunity generated in the participants in the form of the T cells and B cells of their immune system, and the level of immunity needed to protect one from COVID-19 are unknown.

With these preliminary data, along with additional data being generated, Pfizer noted in the statement that the two companies will determine a dose level, and select among multiple vaccine candidates to seek to progress to a large, global safety and efficacy trial, which may involve up to 30,000 healthy participants if regulatory approval to proceed is received.